Risk-based patient selection for systematic biopsy in prostate cancer diagnosis has been adopted in daily clinical practice, either by clinical judgment and PSA testing, or using multivariate risk prediction tools. The use of multivariable risk prediction tools can significantly reduce unnecessary systematic biopsies, without compromising the detection of clinically significant disease. Increasingly multi-parametric magnetic resonance imaging (MRI) is performed, not only in men with a persistent suspicion of prostate cancer after prior negative systematic biopsy, but also at initial screening before the first biopsy. The combination of MRI and multivariate risk prediction tools could potentially enhance prostate cancer diagnosis using multivariate MRI incorporated risk-based models to decide on the need for prostate MRI, but also using MRI results to adjusted risk-based models, and to guide MRI-directed biopsies. In this review, we discuss the diagnostic work-up for clinically significant prostate cancer, where the combination of MRI and multivariate risk prediction tools is integrated, and how together they can contribute to personalized diagnosis.
Today's Top 5
5. What Happens When Local Hospital Closes?
4. New Treatments for Childhood Cancers
3. Insomnia in Cancer Survivors
“Up to 60% of cancer survivors have some form of insomnia, but it is often underdiagnosed and undertreated. Now, people have more choices to manage their insomnia. We need to raise awareness that there are good non-drug options for this condition.” https://t.co/LC6TCYhdQM— Memorial Sloan Kettering Cancer Center (@sloan_kettering) August 21, 2019
2. Timing of ADT in Prostate Cancer
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial - The Lancet Oncology @DrSpratticus @urogeek https://t.co/pPa537AyFO— Brian F. Chapin (@ChapinMD) August 22, 2019